|
Company Information
Regenics AS, is a Norwegian biotechnology company based in Oslo. The business concept is to develop and patent technologies and products for therapeutic wound healing and cosmeceutical applications.
Regenics' proprietary technology is a revolutionary approach to skin regeneration, with power to improve wound healing, stimulate keratinocytes and fibroblasts, regulate skin cell differentiation and stimulate collagen secretion – technologies of benefit both in wound healing and cosmetic applications.
Regenics’ products aim to locally revive the regenerative abilities of skin cells in order to improve wound healing and skin cell proliferation with technologies utilize nature's own ingredients and healing processes to repair tissues by improving cell function and growth.
Regenics follows a proactive research and patent filing strategy to protect its novel technology and to ensure that it has a clear intellectual property path for marketing the product.
Regenics’ innovations include products from biomarine ingredients, including salmon eggs, with unique effects including improved wound healing, regeneration of skin cells, regulation of skin cell differentiation and increased collagen secretion. The transdifferentiation technology was developed by one of the founding partners in Regenics, Dr. Philippe Collas. Dr. Collas is one of the most successful and prolific researchers in the area of cell reprogramming. No product regulating the differentiation state of skin cells currently exists on the market, making Regenics’ product strategy unique. The outstanding scientific team and wide network of international collaborations with academic and industry leaders make Regenics capable of world-class research.
|
